Lumos Pharma
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, focused on developing and commercializing therapeutics for severe, rare, and genetic diseases. The company's lead product, LUM-201, is an oral small molecule currently undergoing Phase 2 clinical trials for pediatric growth hormone deficiency. In addition to its primary focus, Lumos has a licensing agreement with Ellipses Pharma Limited for the development and commercialization of nanoparticle formulations aimed at oncology indications. Founded in 2011, Lumos Pharma also has a commitment to addressing Creatine Transporter Deficiency, leveraging exclusive licenses for technologies developed at the University of Cincinnati and collaborating with key opinion leaders and the National Institutes of Health. The company engages in both clinical and preclinical research, exploring treatments that may enhance immune responses against cancer, and has partnerships for manufacturing its therapeutics.
Top Regions
Top Stages
1 past transactions
Newlink Genetics
Acquisition in 2019
NewLink Genetics is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative immuno-oncology products aimed at enhancing the lives of cancer patients. Established over 15 years ago, the company is driven by a team of experienced industry professionals and physician-scientists. Inspired by personal cancer experiences, NewLink Genetics is committed to advancing research and development in cancer treatments. The company's mission focuses on transforming the cancer treatment landscape and making a meaningful impact on patient outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.